Clinical trials: Atopic Dermatosis
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118792
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis
A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the "Атопик Soothing Cream" in Children with Mild to Moderate Atopic Dermatitis
- Trial name
- NCT02716181
- Testing
- "Атопик Soothing Cream"
- Where
- Russia
- Volunteers
- 74 people
- Sponsor
- Avanta Trading Ltd.
Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
- Trial name
- ROCKET-ASCEND (NCT05882877)
- Testing
- Rocatinlimab
- Where
- 547 sites in United States, Argentina and 40 more
- Volunteers
- 2,621 people
- Sponsor
- Amgen
Atopic Dermatitis
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03531957
- Testing
- ASN002
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 244 people
- Sponsor
- Asana BioSciences
Atopic Dermatitis
Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%
Randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and safety study in subjects with mild to moderate atopic dermatitis.
- Trial name
- C012013 (NCT02031445)
- Testing
- MRX-6
- Where
- 5 sites in Israel
- Volunteers
- 73 people
- Sponsor
- Celsus Therapeutics PLC
Atopic Dermatitis
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy.
- Trial name
- ADsolve (NCT07006792)
- Testing
- Lebrikizumab
- Where
- 66 sites in United States, Argentina and 3 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
In-Use Test With a Cosmetic Product
The aim of the study is to evaluate the tolerance of the product WO 4260 by a dermatologist. Additional objectives of this clinical in-use study are to evaluate the cosmetic features and acceptance of the product by means of a…
- Trial name
- NCT03252730
- Testing
- WO 4260 Cosmetic Product for Topical Use
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi
Dermatitis, Atopic
A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception)…
- Trial name
- NCT04740892
- Testing
- Wash IP, Cream IP
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis (AD)
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
This is a single arm, and open-label phase I study
- Trial name
- NCT07329101
- Testing
- VC005
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD)…
- Trial name
- CHRONOS (NCT02260986)
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 148 sites in United States, Australia and 12 more
- Volunteers
- 740 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Eczema-Prone Skin
Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema
The aim of this exploratory study is to investigate the short- and long-term efficacy and tolerability of a cosmetic product combination consisting of a body lotion and an intensive care product in subjects with atopic eczema…
- Trial name
- AtoCare-OS (NCT05790083)
- Testing
- Body Lotion and Intensive Care
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Atopic Dermatitis
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate Atopic Dermatitis.
- Trial name
- NCT03107611
- Testing
- Pimecrolimus Cream, 1%
- Where
- 27 sites in United States, Dominican Republic and 1 more
- Volunteers
- 654 people
- Sponsor
- Mylan Inc.
Atopic Dermatitis (AD)
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07180511
- Testing
- 10mg QY201 tablet, 20mg QY201 tablet
- Where
- China
- Volunteers
- 460 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic…
- Trial name
- NCT00232011
- Testing
- Pimecrolimus Cream 1%
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Novartis
Dermatitis, Atopic
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.
- Trial name
- NCT05014438
- Testing
- BMS-986166, Branebrutinib
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18…
- Trial name
- NCT05018806
- Testing
- Rilzabrutinib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Clinical Trial to Evaluate the Efficacy and Safety of an Ozonated Oil in Atopic Dermatitis
This clinical trial is designed to evaluate the efficacy, safety, and tolerability of a topical ozonated vegetable oil formulation in paediatric patients with mild-to-moderate atopic dermatitis.
- Trial name
- NCT07744516
- Testing
- ozonated oil, non-ozonated oil
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Laboratorios Ozoaqua
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
- Trial name
- NCT02576938
- Testing
- Baricitinib, Triamcinolone (Optional)
- Where
- 13 sites in United States, Japan
- Volunteers
- 124 people
- Sponsor
- Eli Lilly and Company
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd